Hansoh Pharmaceutical (03692): NDA for Orapeptide Injection Accepted by China's NMPA

Hansoh Pharma(03692) announced that on June 3, 2026, the National Medical Products Administration (NMPA) of China accepted the New Drug Application (NDA) for the Group’s innovative drug, olepatide injection, for long-term weight management in adults with obesity or overweight. Olepatide is a once-weekly glucagon-like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) dual receptor agonist independently developed by the Group.